BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.99) by 13.13 percent. This is a 20.37 percent increase over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $2.73 million which missed the analyst consensus estimate of $3.76 million by 27.37 percent. This is a 33.22 percent decrease over sales of $4.09 million the same period last year.